Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison
| dc.rights.license | open | en_US |
| dc.contributor.author | OHJI, M. | |
| dc.contributor.author | LANZETTA, P. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | KOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535 IDREF: 028739272 | |
| dc.contributor.author | WOJCIECHOWSKI, P. | |
| dc.contributor.author | TAIEB, V. | |
| dc.contributor.author | DESCHASEAUX, C. | |
| dc.contributor.author | JANER, D. | |
| dc.contributor.author | TUCKMANTEL, C. | |
| dc.date.accessioned | 2021-02-08T15:50:24Z | |
| dc.date.available | 2021-02-08T15:50:24Z | |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 0741-238x | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/26184 | |
| dc.description.abstractEn | Purpose To compare visual outcomes and treatment burden between intravitreally administered aflibercept (IVT-AFL) and ranibizumab (RBZ) treat-and-extend (T&E) regimens in patients with wet age-related macular degeneration (wAMD) at 2 years. Methods A systematic literature review was carried out in Medline, EMBASE, and CENTRAL in October 2018. Matching-adjusted indirect comparison (MAIC) and/or individual patient data meta-regression was used to connect ALTAIR (assessing IVT-AFL T&E) with other studies, adjusting for between-trial differences in baseline visual acuity and age or baseline visual acuity, age, and polypoidal choroidal vasculopathy (PCV) status. Sensitivity analyses were conducted to test the robustness of the results, including direct MAIC between IVT-AFL T&E (ALTAIR) and RBZ T&E (CANTREAT and TREX-AMD trials). Results Six randomized controlled trials (RCTs) (ALTAIR, VIEW 1 and 2, CATT, CANTREAT, and TREX) were included in the analysis. IVT-AFL T&E was assessed in one study, ALTAIR (n = 255), while RBZ T&E was assessed in two trials (n = 327). At 2 years, the median difference (95% credibility interval) between IVT-AFL T&E and RBZ T&E regarding the numbers of Early Treatment Diabetic Retinopathy Study (ETDRS) letters gained was not significant (M1: − 2.29 [− 8.10, 3.58]; M2: − 0.55 [− 6.34, 5.29]). IVT-AFL T&E was associated with significantly fewer injections than RBZ-T&E (M1: − 6.12 [− 7.60, − 4.65]; M2: − 5.93 [− 7.42, − 4.45]). Results of the sensitivity analyses were consistent with the main scenarios. Conclusion Patients with wAMD receiving an IVT-AFL T&E regimen achieved and maintained improvement in visual acuity with fewer injections over 2 years compared with RBZ T&E. IVT-AFL T&E may therefore serve as the optimal therapy for wAMD, as it was associated with clinical efficacy and minimized treatment burden. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
| dc.subject | LEHA | |
| dc.title.en | Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison | |
| dc.title.alternative | Adv Ther | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1007/s12325-020-01298-x | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 32222903 | en_US |
| bordeaux.journal | Advances in Therapy | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - U1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | LEHA_BPH | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03135062 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-02-08T15:50:29Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Advances%20in%20Therapy&rft.date=2020&rft.eissn=0741-238x&rft.issn=0741-238x&rft.au=OHJI,%20M.&LANZETTA,%20P.&KOROBELNIK,%20Jean-Francois&WOJCIECHOWSKI,%20P.&TAIEB,%20V.&rft.genre=article |
